NO20020470L - Polymorfismer i det humane MDR-1 genet og deres diagnostiske og terapeutiske anvendelse - Google Patents

Polymorfismer i det humane MDR-1 genet og deres diagnostiske og terapeutiske anvendelse

Info

Publication number
NO20020470L
NO20020470L NO20020470A NO20020470A NO20020470L NO 20020470 L NO20020470 L NO 20020470L NO 20020470 A NO20020470 A NO 20020470A NO 20020470 A NO20020470 A NO 20020470A NO 20020470 L NO20020470 L NO 20020470L
Authority
NO
Norway
Prior art keywords
mdr
vectors
proteins
polynucleotides
gene
Prior art date
Application number
NO20020470A
Other languages
English (en)
Other versions
NO330680B1 (no
NO20020470D0 (no
Inventor
Ulrich Brinkmann
Sven Hoffmeyer
Michel Eichelbaum
Ivar Roots
Original Assignee
Epidauros Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie Ag filed Critical Epidauros Biotechnologie Ag
Publication of NO20020470D0 publication Critical patent/NO20020470D0/no
Publication of NO20020470L publication Critical patent/NO20020470L/no
Publication of NO330680B1 publication Critical patent/NO330680B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
NO20020470A 1999-07-30 2002-01-29 Fremgangsmate for diagnostisering av tilstedevaerelse av en variant av MDR-1 genet, in vitro anvendelse av et oligo- eller polynukleotid, en diagnostisk sammensetning samt en fremgangsmate for identifisering av en MDR-1 inhibitor NO330680B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99114938 1999-07-30
EP00103361 2000-02-22
PCT/EP2000/007314 WO2001009183A2 (en) 1999-07-30 2000-07-28 Polymorphisms in the human mdr-1 gene and applications thereof

Publications (3)

Publication Number Publication Date
NO20020470D0 NO20020470D0 (no) 2002-01-29
NO20020470L true NO20020470L (no) 2002-03-26
NO330680B1 NO330680B1 (no) 2011-06-06

Family

ID=26070560

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20020470A NO330680B1 (no) 1999-07-30 2002-01-29 Fremgangsmate for diagnostisering av tilstedevaerelse av en variant av MDR-1 genet, in vitro anvendelse av et oligo- eller polynukleotid, en diagnostisk sammensetning samt en fremgangsmate for identifisering av en MDR-1 inhibitor
NO20100798A NO20100798L (no) 1999-07-30 2010-06-02 Polymorfismer i det humane MDR-1-genet og deres diagnostiske og terapeutiske anvendelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20100798A NO20100798L (no) 1999-07-30 2010-06-02 Polymorfismer i det humane MDR-1-genet og deres diagnostiske og terapeutiske anvendelse

Country Status (20)

Country Link
US (1) US20050227249A1 (no)
EP (1) EP1232260B1 (no)
JP (2) JP2003510021A (no)
KR (1) KR100814188B1 (no)
AT (1) ATE373710T1 (no)
AU (1) AU1131901A (no)
BG (1) BG65988B1 (no)
CA (2) CA2697207A1 (no)
CZ (1) CZ2002329A3 (no)
DE (1) DE60036487T2 (no)
DK (1) DK1232260T3 (no)
EE (1) EE200200049A (no)
ES (1) ES2292481T3 (no)
HR (1) HRP20020093B1 (no)
HU (1) HUP0201997A3 (no)
MX (1) MXPA02001094A (no)
NO (2) NO330680B1 (no)
PL (1) PL354034A1 (no)
SK (1) SK1502002A3 (no)
WO (1) WO2001009183A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043730A1 (en) * 2000-11-29 2002-06-06 Epidauros Biotechnologie Ag Use of mdr-1 inducers for treating or preventing diseases
US20040191785A1 (en) * 2000-11-29 2004-09-30 Ulrich Brinkmann Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism
AU2002249946C1 (en) 2001-01-12 2009-09-24 Washington State University mdr1 variants and methods for their use
WO2003025174A2 (en) * 2001-09-06 2003-03-27 Bayer Healthcare Ag Regulation of human mrp1-like protein
EP1340818A1 (en) * 2002-02-27 2003-09-03 Epigenomics AG Method and nucleic acids for the analysis of a colon cell proliferative disorder
AU2003280867A1 (en) * 2002-11-04 2004-06-07 Charite-Universitatsme Dizin Berlin Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy
WO2005108605A2 (en) * 2004-05-12 2005-11-17 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
CN101194025A (zh) * 2005-06-13 2008-06-04 弗·哈夫曼-拉罗切有限公司 与急性排异反应有关的impdh2 snp
EP1896614A1 (en) * 2005-06-13 2008-03-12 F. Hoffmann-La Roche Ag MDRl SNP IN ACUTE RETECTION
EP1896608A1 (en) * 2005-06-13 2008-03-12 F. Hoffmann-Roche AG Il10 snp associated with acute rejection
JP2009515524A (ja) * 2005-11-10 2009-04-16 アメリカ合衆国 Ａｂｃｂ１多型バリアントスクリーニング、診断及び処置のための物質及び方法
ES2394529T3 (es) 2007-06-12 2013-02-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nuevos polimorfismos en ABCB1 asociados con una falta de respuesta clínica a medicamentos
KR101033840B1 (ko) * 2011-03-08 2011-05-16 (주)제일엔지니어링건축사사무소 공동주택용 입상관 연결구조
US20180365372A1 (en) * 2017-06-19 2018-12-20 Jungla Inc. Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5206352A (en) * 1986-03-28 1993-04-27 Board Of Trustees Of The University Of Illinois Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
US5928637A (en) * 1987-06-16 1999-07-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of inducing multidrug resistance using human MDR1 cDNA
US5851819A (en) * 1987-06-16 1998-12-22 National Institutes Of Health Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells
JPH02100680A (ja) * 1988-10-05 1990-04-12 Suntory Ltd ヒト正常細胞由来ｍｄｒ関連遺伝子
US5399483A (en) * 1989-03-30 1995-03-21 Suntory Limited Expression of MDR-related gene in yeast cell
US5856104A (en) * 1996-10-28 1999-01-05 Affymetrix, Inc. Polymorphisms in the glucose-6 phosphate dehydrogenase locus
US5830697A (en) * 1997-01-21 1998-11-03 The Board Of Trustees Of The Leland Stanford Junior University P-glycoprotein mutant resistant to cyclosporin modulation

Also Published As

Publication number Publication date
WO2001009183A3 (en) 2002-03-28
NO330680B1 (no) 2011-06-06
US20050227249A1 (en) 2005-10-13
AU1131901A (en) 2001-02-19
JP2003510021A (ja) 2003-03-18
HRP20020093B1 (en) 2011-02-28
NO20020470D0 (no) 2002-01-29
BG65988B1 (bg) 2010-08-31
EE200200049A (et) 2003-04-15
MXPA02001094A (es) 2003-07-21
KR100814188B1 (ko) 2008-03-17
PL354034A1 (en) 2003-12-15
HUP0201997A3 (en) 2005-01-28
ATE373710T1 (de) 2007-10-15
HUP0201997A2 (en) 2002-09-28
WO2001009183A2 (en) 2001-02-08
JP2011142909A (ja) 2011-07-28
CA2697207A1 (en) 2001-02-08
EP1232260B1 (en) 2007-09-19
HRP20020093A2 (en) 2004-06-30
KR20020059347A (ko) 2002-07-12
ES2292481T3 (es) 2008-03-16
CA2376666A1 (en) 2001-02-08
DE60036487T2 (de) 2008-06-19
DK1232260T3 (da) 2008-02-04
DE60036487D1 (de) 2007-10-31
BG106362A (bg) 2002-09-30
NO20100798L (no) 2002-03-26
EP1232260A2 (en) 2002-08-21
CZ2002329A3 (cs) 2002-07-17
CA2376666C (en) 2010-05-25
SK1502002A3 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
Vertegaal Signalling mechanisms and cellular functions of SUMO
Ye et al. Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems
NO20020470L (no) Polymorfismer i det humane MDR-1 genet og deres diagnostiske og terapeutiske anvendelse
Gass et al. Progranulin: an emerging target for FTLD therapies
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
NZ531570A (en) DNA sequences for human angiogenesis genes
BRPI0510206A (pt) método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação
Brooker et al. Cell biology of Parkinson's disease: Mechanisms of synaptic, lysosomal, and mitochondrial dysfunction
NO20021147D0 (no) Polymorfismer i det humane hPXR-genet og deres anvendelse i diagnostiske og terapeutiske applikasjoner
Chang et al. rAAV-CRISPRa therapy corrects Rai1 haploinsufficiency and rescues selective disease features in Smith-Magenis syndrome mice
Morello et al. Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy
Pang et al. High-throughput sequencing offers new insights into 5-hydroxymethylcytosine
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
DK1272663T3 (da) Polymorfier i det humane CYP2B6-gen og deres anvendelse ved diagnostiske og terapeutiske anvendelser
Szyf et al. Epigenetics and well-being: Optimal adaptation to the environment
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
Wentworth Winchester et al. Integration of multimodal data in the developing tooth reveals candidate regulatory loci driving human odontogenic phenotypes
Lozano et al. Profiling IOP-responsive genes in anterior and posterior ocular tissues in the rat CEI glaucoma model
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
DE50312502D1 (de) Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen
Holcomb et al. GRHD PLANNING COMMITTEE
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
WO2004052290A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
NAFEA et al. Study of Vascular Endothelial Growth Factor Gene Polymorphism in Acute Myeloid Leukemia Patients

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees